Oxford University and NIH COVID-19 vaccine shows success in rhesus macaques
A vaccine currently in Phase I clinical trials was effective at inducing immune responses against SARS-CoV-2 in mice and rhesus macaques.
List view / Grid view
A vaccine currently in Phase I clinical trials was effective at inducing immune responses against SARS-CoV-2 in mice and rhesus macaques.
Two antibodies named B38 and H4 could work as a COVID-19 therapeutic by neutralising the virus, say researchers in China.
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
A new kind of dendritic cell has been discovered by researchers and could play a role presenting antigens to other immune cells during respiratory virus infections.
A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.
An antibody that neutralises both SARS-CoV and SARS-CoV-2 in cell cultures has been discovered by researchers and could be used to treat COVID-19.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
By culturing blood cells with mesenchymal stromal cells (MSCs), researchers induced the production of cells with the same functionality as Tregs.
Engineering antibodies found in a llama, researchers have developed a potential COVID-19 therapy which they say can neutralise SARS-CoV-2.
Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
Having developed synthetic antibodies made of VHH complexes, researchers showed that these could be used to combat bunyaviruses successfully.
The US National Institute of Allergy and Infectious Diseases (NIAID) plan outlines four research priorities, including furthering understanding of SARS-CoV-2 viral transmission and pathogenesis and development of animal models.
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
Professor Yehuda Shoenfeld suggests hyperferritinaemia, a condition caused by high ferritin levels, may be causing the severe COVID-19 symptoms.
Using an antibody to a particular malaria protein called PfGARP, researchers have developed a new strategy for designing a malaria vaccine.